A new pharmacological inhibitor of the Cdc7 protein kinase can block replication initiation without activating the replication checkpoint, thus validating replication initiation as a new target class for cancer cell chemotherapy.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Montagnoli, A. et al. Nat. Chem. Biol. 4, 357–365 (2008).
Bell, S.P. & Dutta, A. Annu. Rev. Biochem. 71, 333–374 (2002).
Forsburg, S.L. Microbiol. Mol. Biol. Rev. 68, 109–131 (2004).
Montagnoli, A. et al. J. Biol. Chem. 281, 10281–10290 (2006).
Vanotti, E. et al. J. Med. Chem. 51, 487–501 (2008).
Rights and permissions
About this article
Cite this article
Jackson, P. Stopping replication, at the beginning. Nat Chem Biol 4, 331–332 (2008). https://doi.org/10.1038/nchembio0608-331
This article is cited by
Molecular architecture of the DNA replication origin activation checkpoint
The EMBO Journal (2010)